4-Butylresorcinol, Explained: The Tyrosinase Inhibitor With a Lower IC50 Than Hydroquinone, Kojic Acid, or Arbutin

What it actually is

4-butylresorcinol (INCI: 4-Butylresorcinol, CosIng reference number 54209, chemical formula C10H14O2) is a synthetic resorcinol derivative -- a phenolic ring with a four-carbon butyl chain attached. It isn't fermented or plant-derived the way kojic acid or many K-beauty actives are; it's built specifically to fit into tyrosinase's active site, which is also why its potency profile looks different from ingredients that were originally isolated for other purposes and later found to affect pigmentation as a side effect.

The inhibition is a numbers game, and the numbers are unusual

Tyrosinase is the copper-dependent enzyme that converts tyrosine into melanin precursors, and every common brightening ingredient interferes with it somewhere along that chain. What sets 4-butylresorcinol apart is potency: a 2013 study published in the Journal of the European Academy of Dermatology and Venereology (Kolbe et al.) measured its inhibition of human tyrosinase at an IC50 of roughly 21 micromoles per liter, and about 13.5 micromoles per liter in an artificial skin model -- figures the researchers reported as exceeding hydroquinone, arbutin, and kojic acid by a wide margin. A separate comparative review of depigmenting agents ranked its tyrosinase-inhibiting capacity ahead of ascorbic acid and bakuchiol as well, which puts it in a different potency tier from almost every brightening ingredient this site has covered so far.

Why formulators still use it at low percentages

Because the enzyme-level potency is so high, 4-butylresorcinol doesn't need a 2%-5% concentration the way arbutin does under Korea's MFDS functional-cosmetic notification rules. Ingredient suppliers and formulation literature generally describe cosmetic use in the 0.1%-0.3% range, with some technical data sheets citing tolerance up to roughly 2% before irritation risk rises. That's a narrow, low-dose ingredient in the same category as adenosine or tranexamic acid: small changes in formulated percentage move the effective dose more than the label percentage alone suggests.

It's also a reminder that "low percentage" on an ingredient list isn't automatically a marketing downgrade. Consumers are trained to read higher percentages as stronger formulas, but for an enzyme inhibitor, the relevant number is how much of the ingredient it takes to occupy the active site -- not how much fits comfortably into a bottle. A 0.2% 4-butylresorcinol serum and a 2% arbutin serum are not doing proportionally different amounts of work; they're built around two different dose-response curves entirely.

What the clinical trials actually tested -- and who was in them

The strongest human data on 4-butylresorcinol comes from dermatology trials, not cosmetics testing, and it's worth being precise about that. A 2010 randomized, double-blind, vehicle-controlled split-face trial enrolled 20 patients with diagnosed melasma, applying a 0.1% cream to one side of the face and a vehicle control to the other for eight weeks; the treated side showed measurable improvement over the control. A separate trial using a 0.3% Rucinol serum followed melasma patients for three months and found good-to-fair efficacy reported by 78% of participants, and an Indian multicentric study of a 0.3% cream reported similar tolerability and photographic improvement over eight weeks. These are legitimate, peer-reviewed results -- but every one of them was conducted on people with a diagnosed skin condition, under a dermatologist's supervision, often at concentrations and in formulations that differ from what ends up in a retail serum.

Why that distinction matters for the bottle on your shelf

Melasma is a hormonally and UV-driven pigmentation disorder that this site has already covered in detail, and it isn't something a cosmetic ingredient -- however well-studied -- is positioned to diagnose or treat. If you're seeing persistent, patterned, or worsening dark patches, that's a conversation for a dermatologist, not a shopping decision. What the 4-butylresorcinol research does support is the enzyme-level mechanism: it's a genuinely potent tyrosinase inhibitor, which is why it turns up in general tone-evening and dark-spot cosmetic formulas aimed at sun-exposure-related unevenness, distinct from melasma treatment protocols.

Stability, pairing, and the sunscreen problem every tyrosinase inhibitor shares

4-butylresorcinol is reported in formulation literature as non-photosensitizing and reasonably stable compared with kojic acid's well-documented light and oxidation sensitivity, which makes it easier to pair with other actives. It shows up alongside niacinamide and vitamin C in commercial brightening formulas -- ingredients that work through different points in the pigmentation pathway rather than duplicating the same mechanism -- and in some of the clinical literature it's marketed under the trade name Rucinol rather than listed by its INCI name, which is worth knowing if you're trying to identify it on a label.

None of that matters much without daily sunscreen, though: tyrosinase activity is upregulated by UV exposure, so any inhibitor -- 4-butylresorcinol included -- is working against a stimulus that reapplied SPF, not the brightening serum itself, is what actually controls. Every one of the clinical trials behind this ingredient was run alongside sun protection or sun-avoidance instructions, not as a standalone substitute for it.

Irritation profile and where it sits among pigmentation ingredients

Industry technical data describes 4-butylresorcinol within its typical use range as non-irritating and having low allergenic potential relative to hydroquinone, which carries well-documented sensitization concerns at higher concentrations. That's a more favorable baseline than kojic acid, which this site has covered as carrying a real contact-dermatitis risk near its own concentration ceiling. Favorable industry-reported tolerability isn't the same as a guarantee for any individual, though, and resorcinol-family ingredients can still cause reactions in people with reactive skin. This site has previously broken down the mechanism differences between alpha arbutin, tranexamic acid, and vitamin C, compared potency and stability trade-offs for kojic acid, and looked at how bakuchiol compares to retinol in a head-to-head trial -- 4-butylresorcinol adds a fifth, higher-potency data point to that same mechanism map rather than replacing any of them.

Bottom line

4-butylresorcinol is one of the more potent tyrosinase inhibitors in the published cosmetic-science literature, with IC50 data that outperforms several better-known brighteners at a lower typical use concentration. But "potent in an enzyme assay" and "right for your skin" are separate questions, and the strongest human trials behind it were run on diagnosed melasma patients under clinical supervision -- not a template for self-treating pigmentation at home. If you have persistent or patterned dark patches, see a dermatologist for an actual diagnosis rather than choosing a brightening ingredient by IC50 number. This article explains ingredient mechanisms and does not diagnose or treat any skin condition; patch-test any new 4-butylresorcinol product on a small area first, and consult a dermatologist about persistent or worsening pigmentation.